2023
PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation
Perike S, Gonzalez-Gonzalez F, Abu-Taha I, Damen F, Hanft L, Lizama K, Aboonabi A, Capote A, Aguilar-Sanchez Y, Levin B, Han Z, Sridhar A, Grand J, Martin J, Akar J, Warren C, Solaro R, Ong S, Darbar D, McDonald K, Goergen C, Wolska B, Dobrev D, Wehrens X, McCauley M. PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation. Circulation Research 2023, 133: 758-771. PMID: 37737016, PMCID: PMC10616980, DOI: 10.1161/circresaha.123.322516.Peer-Reviewed Original ResearchConceptsSinus rhythm controlsAtrial hypocontractilityAF inducibilityAtrial contractilityAtrial fibrillationRhythm controlHuman patientsRight atrial appendage tissuePacing-induced AFThromboembolic stroke riskAtrial ejection fractionAtrial appendage tissueAtrial HL-1 cellsHL-1 cellsAtrial strainStroke riskAtrial sizeEjection fractionContractile functionElectrophysiology studyHypocontractilityWestern blotPatientsAtrial myosin light chainSarcomere function
2020
The NCDR Left Atrial Appendage Occlusion Registry
Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ, Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR Left Atrial Appendage Occlusion Registry. Journal Of The American College Of Cardiology 2020, 75: 1503-1518. PMID: 32238316, PMCID: PMC7205034, DOI: 10.1016/j.jacc.2019.12.040.Peer-Reviewed Original ResearchConceptsHospital adverse event ratesAdverse event ratesEvent ratesMean HAS-BLED scoreHAS-BLED scoreHospital adverse eventsMean patient ageAtrial appendage occlusionMedian annual numberMajor bleedingMean CHAMore comorbiditiesVASc scoreWATCHMAN procedureAdverse eventsCommon complicationPatient agePericardial effusionPivotal trialsAppendage occlusionRandomized trialsAtrial fibrillationPatient populationPresent patientPhysician characteristics
2016
Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT)
Lip GY, Waldo AL, Ip J, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen M, Halperin JL, Investigators I. Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). The American Journal Of Cardiology 2016, 118: 1680-1684. PMID: 27665206, DOI: 10.1016/j.amjcard.2016.08.047.Peer-Reviewed Original ResearchConceptsMean therapeutic rangeTherapeutic rangeSAMe-TTAnticoagulation controlDeterminants of timeNew York Heart Association class INew York Heart Association class IVVitamin K antagonist-treated patientsAdditional stroke risk factorsBetter therapeutic rangeGood anticoagulation controlMean TTR valueOverall TTRStroke risk factorsVitamin K antagonistsRisk of strokeNon-US sitesStroke risk assessmentAHRE durationOral anticoagulationK antagonistsOral anticoagulantsRosendaal methodArrhythmia centersAtrial tachyarrhythmias
2015
Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices
Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. European Heart Journal 2015, 36: 1660-1668. PMID: 25908774, DOI: 10.1093/eurheartj/ehv115.Peer-Reviewed Original ResearchConceptsAtrial tachyarrhythmiasMajor bleedingImplanted defibrillatorsInterruption of anticoagulationRemote rhythm monitoringStandard clinical criteriaCardiac resynchronization devicesAT burdenSystemic embolismThromboembolism ratesPrimary endpointComposite endpointBiventricular defibrillatorMedian timeAtrial fibrillationClinical criteriaResynchronization devicesEarly initiationAnticoagulationRhythm monitoringBleedingPatientsPrimary analysisControl groupAtrial electrograms
2009
Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study
Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS, Rohani P, Halperin JL, Investigators F. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. American Heart Journal 2009, 158: 364-370.e1. PMID: 19699858, DOI: 10.1016/j.ahj.2009.07.002.Peer-Reviewed Original ResearchConceptsAtrial high-rate episodesRisk of strokeAnticoagulant therapyAtrial fibrillationAtrial flutterCardiac resynchronization therapy-defibrillator deviceConventional clinical managementRemote rhythm monitoringStudies of anticoagulationRate of strokeOral anticoagulant therapyHigh-rate episodesAdditional risk factorsCRT-D devicesStroke risk stratificationCommon cardiac arrhythmiaAHRE burdenElectrocardiographic documentationMajor bleedingSystemic embolismProphylactic therapyClinical characteristicsStroke riskAnticoagulation decisionsClinical features